Publications
Detailed Information
자궁경부암과 HPV백신 : Human Papillomavirus Vaccine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김미경 | - |
dc.contributor.author | 노재홍 | - |
dc.contributor.author | 송용상 | - |
dc.date.accessioned | 2012-06-04T01:34:22Z | - |
dc.date.available | 2012-06-04T01:34:22Z | - |
dc.date.issued | 2009-12 | - |
dc.identifier.citation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION; Vol.52 12; 1180-1186 | ko_KR |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76748 | - |
dc.description.abstract | Cervical cancer is the second most common cancer affecting women worldwide. Cervical cancer is caused by persistent infection with high-risk types of human papillomavirus (HPV). The most common oncogenic HPV genotypes are 16 and 18, causing approximately 70% of all cervical cancers. Recently, two HPV vaccines, quadrivalent (HPV 6, 11, 16, 18) and bivalent (HPV 16, 18) vaccines, have been licensed and are now marketed in Korea. HPV vaccines are prepared from virus-like particles (VLPs) produced by recombinant technology. Clinical trials have confirmed that both vaccines have high efficiency against persistent infection of HPV 16 or 18 and moderate to severe precancerous lesions. In women who have no evidence of past or current infection with the HPV genotypes in the vaccine, both vaccines show > 90% protection against persistent HPV infection for up to 5 years after vaccination. In addition, vaccine efficacy against precancerous lesions associated with HPV 16/18 was reported to be 100%. Although most clinical trials to date have investigated the effectiveness of HPV vaccines in young females, elderly females and males may also be candidates for HPV vaccines. Since HPV vaccines are prophylactic, the largest impact of vaccination is expected to result from high coverage of young adolescents before exposure to HPV. Cervical cancer screening will still be required, even after HPV vaccines are introduced, although the screening program may need to be adapted to achieve cost-effective reductions in the burden of cervical cancer prevention strategies. | ko_KR |
dc.language.iso | ko | ko_KR |
dc.publisher | KOREAN MEDICAL ASSOC | ko_KR |
dc.subject | Cervical cancer | ko_KR |
dc.subject | Human papillomavirus | ko_KR |
dc.subject | Prevention | ko_KR |
dc.subject | Vaccination | ko_KR |
dc.subject | 자궁경부암 | ko_KR |
dc.subject | 인유두종바이러스 | ko_KR |
dc.subject | 백신 | ko_KR |
dc.subject | 예방 | ko_KR |
dc.title | 자궁경부암과 HPV백신 | ko_KR |
dc.title.alternative | Human Papillomavirus Vaccine | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | Kim, Mi-Kyung | - |
dc.contributor.AlternativeAuthor | No, Jae Hong | - |
dc.contributor.AlternativeAuthor | Song, Yong -Sang | - |
dc.citation.journaltitle | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.description.citedreference | Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7 | - |
dc.description.citedreference | Brown DR, 2009, J INFECT DIS, V199, P926, DOI 10.1086/597307 | - |
dc.description.citedreference | PAAVONEN J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4 | - |
dc.description.citedreference | PATAJA T, 2009, J ADOLESCENT HEALTH, V44, P33 | - |
dc.description.citedreference | Koshiol J, 2008, AM J EPIDEMIOL, V168, P123, DOI 10.1093/aje/kwn036 | - |
dc.description.citedreference | Derkay CS, 2008, LARYNGOSCOPE, V118, P1236, DOI 10.1097/MLG.0b013e31816a7135 | - |
dc.description.citedreference | Franekova M, 2008, UROL ONCOL-SEMIN ORI, V26, P1, DOI 10.1016/j.urolonc.2006.10.011 | - |
dc.description.citedreference | RONCO G, 2008, BMC WOMENS HLTH, V8, P23 | - |
dc.description.citedreference | Smith JF, 2007, HUM VACCINES, V3, P109 | - |
dc.description.citedreference | Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049 | - |
dc.description.citedreference | Villa L, 2007, LANCET, V369, P1861 | - |
dc.description.citedreference | Garland SM, 2007, NEW ENGL J MED, V356, P1928 | - |
dc.description.citedreference | Dunne EF, 2007, JAMA-J AM MED ASSOC, V297, P813 | - |
dc.description.citedreference | 2007, N ENGL J MED, V356, P1915 | - |
dc.description.citedreference | Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469 | - |
dc.description.citedreference | Chung HH, 2006, INT J GYNECOL CANCER, V16, P1833, DOI 10.1111/j.1525-1438.2006.00708.x | - |
dc.description.citedreference | Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S01406736(06)68439-0 | - |
dc.description.citedreference | Mao C, 2006, OBSTET GYNECOL, V107, P18 | - |
dc.description.citedreference | STANLEY M, 2006, VACCINE S1, V24, pS16 | - |
dc.description.citedreference | Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7 | - |
dc.description.citedreference | Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688 | - |
dc.description.citedreference | PARKIN DM, 2003, VACCINE S3, V24 | - |
dc.description.citedreference | PARKIN DM, 2002, CA CANC J CLIN, V55, P74 | - |
dc.description.citedreference | Carter JJ, 2000, J INFECT DIS, V181, P1911 | - |
dc.description.citedreference | HAGENSEE ME, 1993, J VIROL, V67, P315 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.